Some studies of NSCLC patients have thus identified a gene-expression signature composed of four genes (CD274, CXCL9, IFNG, LAG3) that appears to be upregulated in patients that respond to Durvalumab [62]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.